The Biden administration announced the first 10 prescription drugs that will be subject to price negotiations between manufacturers and Medicare as part of the Inflation Reduction Act. The drugs subject to the initial talks this year are Eliquis, made by Bristol-Myers Squibb (BMY), Jardiance, made by Eli Lilly (LLY), Xarelto, made by Johnson & Johnson (JNJ), Januvia, made by Merck (MRK), Farxiga, made by AstraZeneca (AZN), Entresto, made by Novartis (NVS), Enbrel, made by Amgen (AMGN), Imbruvica, made by AbbVie (ABBV), Stelara, made by Johnson & Johnson, and Fiasp and NovoLog insulins made by Novo Nordisk (NVO).
previous post